{"entity":{"type":"insider","cik":"0001688326","url":"/insider/0001688326","json_url":"/insider/0001688326.json","name":"Third Rock Ventures GP IV, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":39,"n_filings":21,"first":"2019-07-22","last":"2025-10-27","span_basis":"filed_date"},"name_variants":[{"name":"Third Rock Ventures GP IV, L.P.","source":"filing","n_filings":21,"first_seen":"2019-07-22","last_seen":"2025-10-27"}],"transactions":[{"id":5025460,"accession":"0001193125-25-251606","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-251606","line_url":"/filing/0001193125-25-251606#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":477401.0,"shares_display":"477,401","price_per_share":10.152,"price_display":"10.15","price_state":"stated","total_value":4846574.952,"total_display":"4,846,574.95","total_whole":"4,846,575","shares_owned_after":13386574.0,"shares_owned_after_display":"13,386,574","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-23","filed_date":"2025-10-27","scope":"insider"},{"id":4578220,"accession":"0001193125-25-223227","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-223227","line_url":"/filing/0001193125-25-223227#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":8.017,"price_display":"8.02","price_state":"stated","total_value":4008500.0,"total_display":"4,008,500.00","total_whole":"4,008,500","shares_owned_after":13863975.0,"shares_owned_after_display":"13,863,975","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-25","filed_date":"2025-09-29","scope":"insider"},{"id":4701270,"accession":"0001193125-25-206453","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-206453","line_url":"/filing/0001193125-25-206453#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":363541.0,"shares_display":"363,541","price_per_share":7.04,"price_display":"7.04","price_state":"stated","total_value":2559328.64,"total_display":"2,559,328.64","total_whole":"2,559,329","shares_owned_after":14363975.0,"shares_owned_after_display":"14,363,975","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-16","filed_date":"2025-09-17","scope":"insider"},{"id":4270525,"accession":"0001193125-25-199177","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-199177","line_url":"/filing/0001193125-25-199177#line-2","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":86459.0,"shares_display":"86,459","price_per_share":7.0395,"price_display":"7.04","price_state":"stated","total_value":608628.1305,"total_display":"608,628.13","total_whole":"608,628","shares_owned_after":14727516.0,"shares_owned_after_display":"14,727,516","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-08","filed_date":"2025-09-09","scope":"insider"},{"id":4270520,"accession":"0001193125-25-199177","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-199177","line_url":"/filing/0001193125-25-199177#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":642906.0,"shares_display":"642,906","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":4500342.0,"total_display":"4,500,342.00","total_whole":"4,500,342","shares_owned_after":14813975.0,"shares_owned_after_display":"14,813,975","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-05","filed_date":"2025-09-09","scope":"insider"},{"id":4237115,"accession":"0000950170-25-111457","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-111457","line_url":"/filing/0000950170-25-111457#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":302194.0,"shares_display":"302,194","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":2115358.0,"total_display":"2,115,358.00","total_whole":"2,115,358","shares_owned_after":15456881.0,"shares_owned_after_display":"15,456,881","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-22","filed_date":"2025-08-26","scope":"insider"},{"id":4497272,"accession":"0000950170-25-110662","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-110662","line_url":"/filing/0000950170-25-110662#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1100000.0,"shares_display":"1,100,000","price_per_share":7.0116,"price_display":"7.01","price_state":"stated","total_value":7712760.0,"total_display":"7,712,760.00","total_whole":"7,712,760","shares_owned_after":15759075.0,"shares_owned_after_display":"15,759,075","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-19","filed_date":"2025-08-21","scope":"insider"},{"id":2679979,"accession":"0000950170-24-107330","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-107330","line_url":"/filing/0000950170-24-107330#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67400.0,"shares_display":"67,400","price_per_share":10.5305,"price_display":"10.53","price_state":"stated","total_value":709755.7,"total_display":"709,755.70","total_whole":"709,756","shares_owned_after":16859075.0,"shares_owned_after_display":"16,859,075","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-13","filed_date":"2024-09-17","scope":"insider"},{"id":2515836,"accession":"0000950170-24-104863","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-104863","line_url":"/filing/0000950170-24-104863#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":75000.0,"shares_display":"75,000","price_per_share":11.5618,"price_display":"11.56","price_state":"stated","total_value":867135.0,"total_display":"867,135.00","total_whole":"867,135","shares_owned_after":16926475.0,"shares_owned_after_display":"16,926,475","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-05","filed_date":"2024-09-09","scope":"insider"},{"id":2828118,"accession":"0000950170-24-103661","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-103661","line_url":"/filing/0000950170-24-103661#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":175000.0,"shares_display":"175,000","price_per_share":11.5983,"price_display":"11.60","price_state":"stated","total_value":2029702.5,"total_display":"2,029,702.50","total_whole":"2,029,703","shares_owned_after":17001475.0,"shares_owned_after_display":"17,001,475","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-30","filed_date":"2024-09-04","scope":"insider"},{"id":3255643,"accession":"0000950170-24-101910","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-101910","line_url":"/filing/0000950170-24-101910#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":11.5466,"price_display":"11.55","price_state":"stated","total_value":288665.0,"total_display":"288,665.00","total_whole":"288,665","shares_owned_after":17176475.0,"shares_owned_after_display":"17,176,475","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-27","filed_date":"2024-08-29","scope":"insider"},{"id":3152773,"accession":"0000950170-24-099253","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-099253","line_url":"/filing/0000950170-24-099253#line-2","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":150000.0,"shares_display":"150,000","price_per_share":10.0928,"price_display":"10.09","price_state":"stated","total_value":1513920.0,"total_display":"1,513,920.00","total_whole":"1,513,920","shares_owned_after":17201475.0,"shares_owned_after_display":"17,201,475","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-19","filed_date":"2024-08-20","scope":"insider"},{"id":3152772,"accession":"0000950170-24-099253","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-099253","line_url":"/filing/0000950170-24-099253#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":135000.0,"shares_display":"135,000","price_per_share":9.7885,"price_display":"9.79","price_state":"stated","total_value":1321447.5,"total_display":"1,321,447.50","total_whole":"1,321,448","shares_owned_after":17351475.0,"shares_owned_after_display":"17,351,475","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-16","filed_date":"2024-08-20","scope":"insider"},{"id":3111731,"accession":"0000950170-24-089474","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-089474","line_url":"/filing/0000950170-24-089474#line-3","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":9.8,"price_display":"9.80","price_state":"stated","total_value":392000.0,"total_display":"392,000.00","total_whole":"392,000","shares_owned_after":17486475.0,"shares_owned_after_display":"17,486,475","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-01","filed_date":"2024-08-01","scope":"insider"},{"id":3111727,"accession":"0000950170-24-089474","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-089474","line_url":"/filing/0000950170-24-089474#line-2","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":9.9338,"price_display":"9.93","price_state":"stated","total_value":993380.0,"total_display":"993,380.00","total_whole":"993,380","shares_owned_after":17526475.0,"shares_owned_after_display":"17,526,475","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-31","filed_date":"2024-08-01","scope":"insider"},{"id":3111722,"accession":"0000950170-24-089474","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-089474","line_url":"/filing/0000950170-24-089474#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":95000.0,"shares_display":"95,000","price_per_share":9.8012,"price_display":"9.80","price_state":"stated","total_value":931114.0,"total_display":"931,114.00","total_whole":"931,114","shares_owned_after":17626475.0,"shares_owned_after_display":"17,626,475","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-30","filed_date":"2024-08-01","scope":"insider"},{"id":2589375,"accession":"0000950170-24-087862","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-087862","line_url":"/filing/0000950170-24-087862#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":9.839,"price_display":"9.84","price_state":"stated","total_value":491950.0,"total_display":"491,950.00","total_whole":"491,950","shares_owned_after":17721475.0,"shares_owned_after_display":"17,721,475","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-26","filed_date":"2024-07-30","scope":"insider"},{"id":2177468,"accession":"0000950170-24-086894","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-086894","line_url":"/filing/0000950170-24-086894#line-2","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100599.0,"shares_display":"100,599","price_per_share":9.8686,"price_display":"9.87","price_state":"stated","total_value":992771.2914,"total_display":"992,771.29","total_whole":"992,771","shares_owned_after":17771475.0,"shares_owned_after_display":"17,771,475","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-25","filed_date":"2024-07-26","scope":"insider"},{"id":2177464,"accession":"0000950170-24-086894","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-086894","line_url":"/filing/0000950170-24-086894#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200000.0,"shares_display":"200,000","price_per_share":9.8158,"price_display":"9.82","price_state":"stated","total_value":1963160.0,"total_display":"1,963,160.00","total_whole":"1,963,160","shares_owned_after":17872074.0,"shares_owned_after_display":"17,872,074","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-24","filed_date":"2024-07-26","scope":"insider"},{"id":2461393,"accession":"0000950170-24-086051","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-086051","line_url":"/filing/0000950170-24-086051#line-2","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125000.0,"shares_display":"125,000","price_per_share":9.7868,"price_display":"9.79","price_state":"stated","total_value":1223350.0,"total_display":"1,223,350.00","total_whole":"1,223,350","shares_owned_after":18072074.0,"shares_owned_after_display":"18,072,074","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-23","filed_date":"2024-07-24","scope":"insider"},{"id":2461388,"accession":"0000950170-24-086051","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-086051","line_url":"/filing/0000950170-24-086051#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":262740.0,"shares_display":"262,740","price_per_share":9.7819,"price_display":"9.78","price_state":"stated","total_value":2570096.406,"total_display":"2,570,096.41","total_whole":"2,570,096","shares_owned_after":18197074.0,"shares_owned_after_display":"18,197,074","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-22","filed_date":"2024-07-24","scope":"insider"},{"id":2205809,"accession":"0000950170-24-085256","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-085256","line_url":"/filing/0000950170-24-085256#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":191490.0,"shares_display":"191,490","price_per_share":9.8098,"price_display":"9.81","price_state":"stated","total_value":1878478.602,"total_display":"1,878,478.60","total_whole":"1,878,479","shares_owned_after":18459814.0,"shares_owned_after_display":"18,459,814","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-18","filed_date":"2024-07-22","scope":"insider"},{"id":2827556,"accession":"0000950170-24-084580","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-084580","line_url":"/filing/0000950170-24-084580#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":550171.0,"shares_display":"550,171","price_per_share":9.7903,"price_display":"9.79","price_state":"stated","total_value":5386339.1413,"total_display":"5,386,339.14","total_whole":"5,386,339","shares_owned_after":18651304.0,"shares_owned_after_display":"18,651,304","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-17","filed_date":"2024-07-18","scope":"insider"},{"id":2767594,"accession":"0000950170-24-018198","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-018198","line_url":"/filing/0000950170-24-018198#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Tango Therapeutics, Inc.","issuer_ticker":"TNGX","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":162500.0,"shares_display":"162,500","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":1950000.0,"total_display":"1,950,000.00","total_whole":"1,950,000","shares_owned_after":19201475.0,"shares_owned_after_display":"19,201,475","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-20","filed_date":"2024-02-21","scope":"insider"},{"id":8279291,"accession":"0000899243-23-004411","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-004411","line_url":"/filing/0000899243-23-004411#line-2","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Magenta Therapeutics, Inc.","issuer_ticker":"MGTA","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500000.0,"shares_display":"1,500,000","price_per_share":0.82,"price_display":"0.82","price_state":"stated","total_value":1230000.0,"total_display":"1,230,000.00","total_whole":"1,230,000","shares_owned_after":3058204.0,"shares_owned_after_display":"3,058,204","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-08","filed_date":"2023-02-09","scope":"insider"},{"id":8279286,"accession":"0000899243-23-004411","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-004411","line_url":"/filing/0000899243-23-004411#line-1","is_derivative":false,"issuer_cik":"0001688325","issuer_name":"Magenta Therapeutics, Inc.","issuer_ticker":"MGTA","issuer_name_source":null,"issuer_url":"/issuer/0001688325","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2200000.0,"shares_display":"2,200,000","price_per_share":0.83,"price_display":"0.83","price_state":"stated","total_value":1826000.0,"total_display":"1,826,000.00","total_whole":"1,826,000","shares_owned_after":4558204.0,"shares_owned_after_display":"4,558,204","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-07","filed_date":"2023-02-09","scope":"insider"},{"id":4973131,"accession":"0000899243-21-002117","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000899243-21-002117","line_url":"/filing/0000899243-21-002117#line-12","is_derivative":false,"issuer_cik":"0001180428","issuer_name":"Relay Therapeutics, Inc.","issuer_ticker":"RLAY","issuer_name_source":null,"issuer_url":"/issuer/0001180428","owner_cik":null,"owner_name":"Third Rock Ventures IV, L.P.; LEVIN MARK J; TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures III, L.P.; TRV GP III, LLC; STARR KEVIN P; TEPPER ROBERT I; Third Rock Ventures GP III, L.P.","owner_display_name":"Third Rock Ventures IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1965294.0,"shares_display":"1,965,294","price_per_share":41.0,"price_display":"41.00","price_state":"stated","total_value":80577054.0,"total_display":"80,577,054.00","total_whole":"80,577,054","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-01-14","filed_date":"2021-01-14","scope":"insider"},{"id":4973127,"accession":"0000899243-21-002117","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0000899243-21-002117","line_url":"/filing/0000899243-21-002117","is_derivative":false,"issuer_cik":"0001180428","issuer_name":"Relay Therapeutics, Inc.","issuer_ticker":"RLAY","issuer_name_source":null,"issuer_url":"/issuer/0001180428","owner_cik":null,"owner_name":"Third Rock Ventures IV, L.P.; LEVIN MARK J; TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures III, L.P.; TRV GP III, LLC; STARR KEVIN P; TEPPER ROBERT I; Third Rock Ventures GP III, L.P.","owner_display_name":"Third Rock Ventures IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2157100.0,"shares_display":"2,157,100","price_per_share":40.125936493440264,"price_display":"40.13","price_state":"stated","total_value":86555657.61,"total_display":"86,555,657.61","total_whole":"86,555,658","shares_owned_after":7803242.0,"shares_owned_after_display":"7,803,242","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-13","filed_date":"2021-01-14","scope":"insider","n_lines":10},{"id":4973079,"accession":"0000899243-21-002117","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-002117","line_url":"/filing/0000899243-21-002117#line-1","is_derivative":false,"issuer_cik":"0001180428","issuer_name":"Relay Therapeutics, Inc.","issuer_ticker":"RLAY","issuer_name_source":null,"issuer_url":"/issuer/0001180428","owner_cik":null,"owner_name":"Third Rock Ventures IV, L.P.; LEVIN MARK J; TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures III, L.P.; TRV GP III, LLC; STARR KEVIN P; TEPPER ROBERT I; Third Rock Ventures GP III, L.P.","owner_display_name":"Third Rock Ventures IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500000.0,"shares_display":"1,500,000","price_per_share":40.0,"price_display":"40.00","price_state":"stated","total_value":60000000.0,"total_display":"60,000,000.00","total_whole":"60,000,000","shares_owned_after":9051115.0,"shares_owned_after_display":"9,051,115","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-12","filed_date":"2021-01-14","scope":"insider"},{"id":8024482,"accession":"0000899243-19-020029","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-020029","line_url":"/filing/0000899243-19-020029#line-2","is_derivative":false,"issuer_cik":"0001680581","issuer_name":"Fulcrum Therapeutics, Inc.","issuer_ticker":"FULC","issuer_name_source":null,"issuer_url":"/issuer/0001680581","owner_cik":null,"owner_name":"TRV GP IV, LLC; Third Rock Ventures GP IV, L.P.; Third Rock Ventures IV, L.P.","owner_display_name":"TRV GP IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":81250.0,"shares_display":"81,250","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":1300000.0,"total_display":"1,300,000.00","total_whole":"1,300,000","shares_owned_after":2343154.0,"shares_owned_after_display":"2,343,154","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-22","filed_date":"2019-07-22","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001819133","name":"Tango Therapeutics, Inc.","url":"/issuer/0001819133","role":"Ten percent owner","n_filings":18,"first_seen":"2024-02-21","last_seen":"2025-10-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001690585","name":"Magenta Therapeutics, Inc.","url":"/issuer/0001690585","role":"Ten percent owner","n_filings":1,"first_seen":"2023-02-09","last_seen":"2023-02-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001812364","name":"Relay Therapeutics, Inc.","url":"/issuer/0001812364","role":"Ten percent owner","n_filings":1,"first_seen":"2021-01-14","last_seen":"2021-01-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001680581","name":"Fulcrum Therapeutics, Inc.","url":"/issuer/0001680581","role":"Ten percent owner","n_filings":1,"first_seen":"2019-07-22","last_seen":"2019-07-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001688326","retrieved_at":"2026-08-23T22:24:36+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}